Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГКУ 1586 Военный клинический госпиталь Минобороны России. 142110, Россия, Московская область, Подольск, ул. Маштакова, д. 4 2ФГБУ Московский НИИ психиатрии – филиал ФГБУ Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского Минздрава России. 107076, Россия, Москва, ул. Потешная, д. 3
T.A.Pavlova1, I.V.Dorovskikh1, L.N.Gorobets2 1 Federal 1586 Military Clinical Hospital the Russian Defense Ministry 2 Moscow Research Institute of Psychiatry – Branch of Federal Medical Research Center of Psychiatry and Narcology of the Ministry of Health Ministry of the Russian Federation. 107076, Russian Federation, Moscow, ul. Poteshnaia, d. 3
Список исп. литературыСкрыть список 1. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591–8. 2. Atlantis E, Browning C, Sims J, Kendig H. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010; 25: 688–96. 3. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med 2006; 23: 445–8. 4. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300. 5. Breum L, Bjerre U, Bak JF et al. Long-term effects of fluoxetine on glycemic control in obese patients with noninsulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995; 44: 1570–6. 6. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79: 61–7. 7. Campayo A, de Jonge P, Roy JF et al. ZARADEMP Project. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 2010; 167: 580–8. 8. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York, University of York, 2009. 9. Chen YC, Hung YJ et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007; 103: 257–61. 10. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabetes Med 1995; 12: 416–8. 11. Crombie I. The Pocket Guide to Critical Appraisal. London, BMJ Publishing Group, 1996. 12. Crucitti A, Zhang Q, Nilsson M et al. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis. Curr Med Res Opin 2010; 26: 2579–88. 13. Daubresse JC, Kolanowski J, Krzentowski G et al. Usefulness of fluoxetine in obese noninsulin-dependent diabetics: a multicenter study. Obes Res 1996; 4: 391–6. 14. Derijks HJ, Heerdink ER, de Koning FH et al. The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiol Drug Saf 2008; 17: 336–44. 15. Derijks HJ, Meyboom RHB, Heerdink ER et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008; 64: 531–8. 16. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 1999; 51: 741–3. 17. Ghaeli P, Shahsavand E, Mesbahi M et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24: 386–8. 18. Goldstein DJ, Lu Y, Detke MJ et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–18. 19. Goodnick PJ, Kumar A, Henry JH et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997; 33: 261–4. 20. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord 1992; 16: 193–8. 21. Hardy T, Sachson R, Shen S et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30: 21–6. 22. Hennings JM, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. Curr Pharm Des 2012; 18: 5900–19. 23. Himmerich H, Fulda S, Schaaf L et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006; 29: 170. 24. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125–35. 25. Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999; 22: 862–3. 26. Ivanova A, Nitka D, Schmitz N. Epidemiology of antidepressant medication use in the Canadian diabetes population. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 911–9. 27. Kadiroglu AK, Sit D, Kayabasi H et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22: 241–5. 28. Katon W, Unützer J, Fan MY et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care 2006; 29: 265–70. 29. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13: 7–23. 30. Kauffman RP, Castracane VD, White DL et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and nondepressed euglycemic women of reproductive age. Gynecol Endocrinol 2005; 21: 129–37. 31. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharmacol 2011; 33: 484–92. 32. Khoza S, Barner JC, Bohman TM et al. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol 2012; 68: 1295–302. 33. Kinder LS, Katon WJ, Ludman E et al. Improving depression care in patients with diabetes and multiple complications. J Gen Intern Med 2006; 21: 1036–41. 34. Kivimäki M, Batty GD, Jokela M et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70: 978–84. 35. Kivimäki M, Hamer M, Batty GD et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a populationbased study. Diabetes Care 2010; 33: 2611–6. 36. Kivimäki M, Tabak AG, Lawlor DA et al. Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study. Diabetes Care 2010; 33: 1471–6. 37. Knol MJ, Geerlings MI, Egberts AC et al. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol 2007; 22: 382–6. 38. Knol MJ, Geerlings MI, Grobbee DE et al. Antidepressant use before and after initiation of diabetes mellitus treatment. Diabetologia 2009; 52: 425–32. 39. Kutnowski M, Daubresse JC, Friedman H et al. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes Relat Metab Disord 1992 (Suppl. 16): 63–6. 40. Laimer M, Kramer-Reinstadler K, Rauchenzauner M et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–4. 41. Lin EH, Von Korff M, Ciechanowski P et al. Treatment adjustment and medication adherence for complex patients with diabetes, heart disease, and depression: a randomized controlled trial. Ann Fam Med 2012; 10: 6–14. 42. Lustman PJ, Clouse RE, Nix BD et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 521–9. 43. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; p. 618–23. 44. Lustman PJ, Griffith LS, Clouse RAYE, Kenneth E. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 250: 241–50. 45. Lustman PJ, Williams MM, Sayuk GS et al. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30: 459–66. 46. Ma Y, Balasubramanian R, Pagoto SL et al. Elevated depressive symptoms, antidepressant use, and diabetes in a large multiethnic national sample of postmenopausal women. Diabetes Care 2011; 34: 2390–2. 47. Maheux P, Ducros F, Bourque J et al. Fluoxetine improves insulin sensitivity in obese patients with noninsulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21: 97–102. 48. McIntyre RS, Soczynska JK, Konarski JZ. Kennedy S.H. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5: 157–68. 49. Mezuk B, Johnson-Lawrence V, Lee H et al. Is ignorance bliss? Depression, antidepressants, and the diagnosis of prediabetes and type 2 diabetes. Health Psychol 2013; 32: 254–63. 50. Moosa MYH, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23: 549–52. 51. National Health Executive. Available from: http://www.nationalhealthexecutive. com/Health-Care-News/antidepressant. 52. O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994; 11: 105–10. 53. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 2007; 8: 34. 54. Pan A, Sun Q, Okereke OI et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 2012; 55: 63–72. 55. Petticrew M, Roberts H. Systematic Reviews in the Social Sciences: A Practical Guide. Oxford: Blackwell, 2006. 56. Pinar M, Gulsun M, Tasci I et al. Maprotiline induced weight gain in depressive disorder: changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 135–9. 57. Potter van Loon BJ, Radder JK, Frölich M et al. Fluoxetine increases insulin action in obese type II (noninsulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992; 16 (Suppl. 4): 55–61. 58. Pyykkönen AJ, Räikkönen K, Tuomi T et al. Depressive symptoms, antidepressant medication use, and insulin resistance: the PPP-Botnia Study. Diabetes Care 2011; 34: 2545–7. 59. Pyykkönen AJ, Räikkönen K, Tuomi T et al. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann Med 2012; 44: 279–88. 60. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006; 67: 1974–82. 61. Rubin RR, Ma Y, Peyrot M et al. Diabetes Prevention Program Research Group. Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 2010; 33: 2549–51. 62. Rubin RR, Ma Y, Marrero DG et al. Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31: 420–6. 63. Sansone RA, Sansone LA. Driving on antidepressants: cruising for a crash? Psychiatry (Edgmont) 2009; 6: 13–6. 64. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259–72. 65. Sheldon TA. Making evidence synthesis more useful for management and policymaking. J Health Serv Res Policy 2005; 10 (Suppl. 1): 1–5. 66. Van Reedt Dortland A, Giltay E, van Veen T et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010; 122: 30–9. 67. Wasan AD, Ossanna MJ, Raskin J et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Saf 2009; 4: 22–9. 68. Weber-Hamann B, Gilles M, Lederbogen F et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856–61. 69. Weber-Hamann B, Gilles M, Schilling C et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 2008; 28: 581–4. 70. Weber-Hamann B, Kopf D, Lederbogen F et al. Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology 2005; 81: 200–4. 71. Wilkins TL, Sambamoorthi U. Antidepressant use, depression, lifestyle factors, and new-onset diabetes. Int Clin Psychopharmacol 2011; 26: 159–68.